Rédaction Africa Links 24 with Uganda Monitor
Published on 2024-04-15 11:17:31
The National Drug Authority (NDA) has reassured citizens in Uganda that a specific batch of cough syrup, which was recalled in Kenya due to safety concerns, is not present in the Ugandan market. The cough syrup in question, Benylin Paediatric Cough Syrup Batch 329304, was found to have unacceptably high levels of Diethylene Glycol (DG), a potentially fatal substance, prompting recalls in countries like Kenya, Nigeria, and South Africa.
Mr Abiaz Rwamwiri, NDA spokesperson, confirmed that the affected batch was manufactured in 2021 and never made its way to Uganda. Through collaboration with the registered importer and independent market surveillance, the NDA verified that the recalled batch is not on the market in Uganda. This proactive approach by the authority ensures the safety of consumers.
The recall in Kenya was initiated by the Pharmacy and Poisons Board and led to similar actions in Nigeria and South Africa. The affected batches were reportedly sold in various African nations, including Kenya, Tanzania, Rwanda, Eswatini, and Nigeria. This widespread issue stemmed from a World Health Organization (WHO) report in August 2023, which highlighted high levels of DG in an Indian-made cough syrup found in Iraq.
The WHO considers DG to be toxic to humans and capable of causing serious injury or death. In response to these findings, the NDA is taking precautionary measures to protect consumers in Uganda. The authority is closely monitoring the safety of cough syrups in the market, conducting analyses for DG and Ethylene Glycol levels to ensure compliance with safety standards.
Consumers are encouraged to report any adverse reactions to cough syrup use in children through the NDA’s WhatsApp hotline (0740002070). By staying vigilant and proactive in their oversight, the NDA aims to safeguard the health and well-being of the public.
In conclusion, while the specific batch of cough syrup identified in the recall is not present in Uganda, the NDA remains committed to ensuring consumer safety. Through collaboration, surveillance, and analysis, the authority is taking necessary steps to prevent any potential risks associated with cough syrup consumption. Stay informed, report any concerns, and prioritize safety when it comes to pharmaceutical products.
Read the original article on Uganda Monitor
